Study will utilize Afrezza inhaled insulin and the One Drop digital diabetes care platform Last May, MannKind (maker of Afrezza) and One Drop announced a collaboration to focus on three consumer areas:

1. Access, Cost Savings and Convenience initiatives, intended to simplify the complexity of starting and staying on mealtime insulin. 2. Customized Coaching and Engagement designed to help people on Afrezza achieve the American Diabetes Association (ADA) recommendation of an A1C goal of less than 7%. 3. Design Innovation around packaging and exploration of a reusable Afrezza Inhaler with integrated Bluetooth technology.

Today, One Drop and Mannkind launched a study to evaluate the effectiveness of One Drop | Premium (i.e., One Drop | Mobile app, One Drop | Chrome meter and test strips, One Drop | Experts coaching service) and Afrezza (MannKind's inhaled rapid-acting mealtime insulin) when used together.  

  Interested in participating? Learn more here.

People with type 2 diabetes who meet inclusion criteria will be randomized to one of two treatment arms: Afrezza with One Drop | Premium – or – One Drop | Premium alone. Changes in hemoglobin A1C, quality of life, self-care, treatment satisfaction, and other metrics will be assessed.